Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $13.60.

A number of research firms recently issued reports on OBIO. B. Riley Financial lowered their target price on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Barclays raised their price target on shares of Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Orchestra BioMed in a research report on Thursday, May 14th. Finally, Chardan Capital restated a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a research report on Thursday, March 12th.

Orchestra BioMed Stock Performance

NASDAQ:OBIO opened at $3.90 on Tuesday. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $5.42. The firm’s fifty day simple moving average is $4.12 and its 200 day simple moving average is $4.27. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $233.53 million, a PE ratio of -4.02 and a beta of 0.50.

Orchestra BioMed (NASDAQ:OBIO) last posted its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. On average, sell-side analysts anticipate that Orchestra BioMed will post -1.47 EPS for the current year.

Insider Activity at Orchestra BioMed

In related news, insider David P. Hochman purchased 10,000 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were bought at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the transaction, the insider directly owned 1,086,467 shares of the company’s stock, valued at approximately $4,660,943.43. This trade represents a 0.93% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jason Aryeh purchased 8,971 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was bought at an average price of $3.90 per share, for a total transaction of $34,986.90. Following the completion of the transaction, the director directly owned 117,453 shares in the company, valued at approximately $458,066.70. The trade was a 8.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 49,636 shares of company stock valued at $200,981. Company insiders own 7.50% of the company’s stock.

Institutional Trading of Orchestra BioMed

Hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new stake in Orchestra BioMed in the 4th quarter worth $38,000. Virtu Financial LLC bought a new position in shares of Orchestra BioMed during the 4th quarter worth about $57,000. Creative Planning bought a new position in shares of Orchestra BioMed during the 2nd quarter worth about $40,000. XTX Topco Ltd bought a new position in shares of Orchestra BioMed during the 2nd quarter worth about $45,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Orchestra BioMed during the 4th quarter worth about $76,000. 53.20% of the stock is currently owned by institutional investors and hedge funds.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.